Vasculitis update, 2007

Bulletin of the NYU Hospital for Joint Diseases

Volumn 65, Issue 3, 2007, Pages 212-214

  Yazici, Yusuf ^a,b,c  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NYU HOSPITAL FOR JOINT DISEASES   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; RITUXIMAB; STEROID; ANTIRHEUMATIC AGENT;

ANCA ASSOCIATED VASCULITIS; BLINDNESS; BRAIN ISCHEMIA; CENTRAL RETINA ARTERY OCCLUSION; CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; GIANT CELL ARTERITIS; HEART INFARCTION; HUMAN; ISCHEMIC OPTIC NEUROPATHY; MEDICAL DECISION MAKING; MICROSCOPIC POLYANGIITIS; REMISSION; REVIEW; STROKE; TREATMENT DURATION; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; VASCULITIS; WEGENER GRANULOMATOSIS;

ADRENAL CORTEX HORMONES; ANTICOAGULANTS; ANTIRHEUMATIC AGENTS; ASPIRIN; CYCLOPHOSPHAMIDE; GIANT CELL ARTERITIS; HUMANS; METHOTREXATE; WEGENER GRANULOMATOSIS;

EID: 38449122069     PISSN: 19369719     EISSN: 19369727     Source Type: Journal    
DOI: None     Document Type: Review

References (13)

1. Gonzalez-Gay MA, Garcia-Porrua C, Miranda-Filloy JA. Giant cell arteritis: Diagnosis and therapeutic management. Curr Rheumatol Rep. 2006 Aug;8(4):299-302.
2. Nuenninghoff DM, Matteson EL. The role of disease-modifying antirheumatic drugs in the treatment of giant cell arteritis. Clin Exp Rheumatol. 2003 Nov-Dec;21(6 Suppl 32):S29-34.
3. Nesher G, Berkun Y, Mates M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004;50:1332-7.
4. Hellmann DB. Low-dose aspirin in the treatment of giant cell arteritis. 2004;50:1026-7.
5. Lee MS, Smith SD, Galor A, Hoffman GS. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006 Oct;54(10):3306-9.
6. Bacon PA. The spectrum of Wegener's granulomatosis and disease relapse. N Engl J Med. 2005 Jan 27;352(4):330-2.
7. Jennette JC, Falk RJ, Andrassy K, et al. Nomenclature of systemic vasculitides. Proposal of an international consensus conference. Arthritis Rheum. 1994 Feb;37(2):187-92.
8. Jayne D, Rasmussen N, Andrassy K, et al; European Vasculitis Study Group. A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies. N Engl J Med. 2003 Jul 3;349(1):36-44.
9. De Groot K, Rasmussen N, Bacon PA, et al. Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis. Arthritis Rheum. 2005 Aug;52(8):2461-9.
10. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med. 2005 Jan 27;352(4):351-61.
11. Stone JH, Holbrook JT, Marriott MA, et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum. 2006 May;54(5):1608-18.
12. Flossmann O, Jones RB, Jayne DR, Luqmani RA. Should rituximab be used to treat antineutrophil cytoplasmic antibody associated vasculitis? Ann Rheum Dis. 2006 Jul;65(7):841-4.
13. Aries PM, Hellmich B, Voswinkel J, et al. Lack of efficacy of rituximab in Wegener's granulomatosis with refractory granulomatous manifestations. Ann Rheum Dis. 2006 Jul;65(7):853-8.